R-CHOP chemoimmunotherapy followed by autologous transplantation for the treatment of diffuse large B-cell lymphoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Hong Ghi | - |
dc.contributor.author | Choi, Yunsuk | - |
dc.contributor.author | Kim, Sung-Yong | - |
dc.contributor.author | Kim, Inho | - |
dc.contributor.author | Kim, Yeo-Kyeoung | - |
dc.contributor.author | Kim, Yang Soo | - |
dc.contributor.author | Lee, Ho Sup | - |
dc.contributor.author | Kim, Seok Jin | - |
dc.contributor.author | Kim, Jeong-A | - |
dc.contributor.author | Park, Byeong-Bae | - |
dc.contributor.author | Park, Jinny | - |
dc.contributor.author | Shim, Hyeok | - |
dc.contributor.author | Eom, Hyeon Seok | - |
dc.contributor.author | Lee, Junglim | - |
dc.contributor.author | Park, Sung Kyu | - |
dc.contributor.author | Cheong, June-Won | - |
dc.contributor.author | Park, Keon Woo | - |
dc.date.accessioned | 2022-07-16T04:26:09Z | - |
dc.date.available | 2022-07-16T04:26:09Z | - |
dc.date.created | 2021-05-13 | - |
dc.date.issued | 2014-06 | - |
dc.identifier.issn | 2287-979X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/159779 | - |
dc.description.abstract | Background: We investigated factors that influence outcomes in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab combined with the CHOP regimen (R-CHOP) followed by upfront autologous stem cell transplantation (Auto-SCT). Methods: We retrospectively evaluated survival differences between subgroups based on the age-adjusted International Prognostic Index (aaIPI) and revised-IPI (R-IPI) at diagnosis, disease status, and positron emission tomographic/computerized tomographic (PET/CT) status at transplantation in 51 CD20-positive DLBCL patients treated with R-CHOP followed by upfront Auto-SCT. Results: Patients had either stage I/II bulky disease (5.9%) or stage III/IV disease (94.1%). The median patient age at diagnosis was 47 years (range, 22-66 years); 53.3% and 26.7% had high-intermediate and high risks according to aaIPI, respectively. At the time of Auto-SCT, 72.5% and 27.5% experienced complete (CR) and partial remission (PR) after R-CHOP, respectively. The median time from diagnosis to Auto-SCT was 7.27 months (range, 3.4-13.4 months). The 5-year overall (OS) and progression-free survival (PFS) were 77.3% and 72.4%, respectively. The 5-year OS and PFS rates according to aaIPI, R-IPI, and PET/CT status did not differ between the subgroups. More importantly, the 5-year OS and PFS rates of the patients who achieved PR at the time of Auto-SCT were not inferior to those of the patients who achieved CR (P=0.223 and 0.292, respectively). Conclusion: Survival was not influenced by the aaIPI and R-IPI at diagnosis, disease status, or PET/CT status at transplantation, suggesting that upfront Auto-SCT might overcome unfavorable outcomes attributed to PR after induction chemoimmunotherapy. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Korean Society of Hematology | - |
dc.title | R-CHOP chemoimmunotherapy followed by autologous transplantation for the treatment of diffuse large B-cell lymphoma | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Byeong-Bae | - |
dc.identifier.doi | 10.5045/br.2014.49.2.107 | - |
dc.identifier.scopusid | 2-s2.0-84903534435 | - |
dc.identifier.bibliographicCitation | Blood Research, v.49, no.2, pp.107 - 114 | - |
dc.relation.isPartOf | Blood Research | - |
dc.citation.title | Blood Research | - |
dc.citation.volume | 49 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 107 | - |
dc.citation.endPage | 114 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001882811 | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordPlus | cyclophosphamide | - |
dc.subject.keywordPlus | doxorubicin | - |
dc.subject.keywordPlus | fluorodeoxyglucose f 18 | - |
dc.subject.keywordPlus | prednisolone | - |
dc.subject.keywordPlus | rituximab | - |
dc.subject.keywordPlus | vincristine | - |
dc.subject.keywordPlus | adult | - |
dc.subject.keywordPlus | aged | - |
dc.subject.keywordPlus | article | - |
dc.subject.keywordPlus | autologous stem cell transplantation | - |
dc.subject.keywordPlus | cancer combination chemotherapy | - |
dc.subject.keywordPlus | cancer grading | - |
dc.subject.keywordPlus | cancer immunotherapy | - |
dc.subject.keywordPlus | cancer radiotherapy | - |
dc.subject.keywordPlus | cancer recurrence | - |
dc.subject.keywordPlus | cancer regression | - |
dc.subject.keywordPlus | cancer risk | - |
dc.subject.keywordPlus | cancer survival | - |
dc.subject.keywordPlus | cause of death | - |
dc.subject.keywordPlus | computer assisted emission tomography | - |
dc.subject.keywordPlus | controlled study | - |
dc.subject.keywordPlus | female | - |
dc.subject.keywordPlus | follow up | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | International Prognostic Index | - |
dc.subject.keywordPlus | lactic acidosis | - |
dc.subject.keywordPlus | large cell lymphoma | - |
dc.subject.keywordPlus | major clinical study | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | outcome assessment | - |
dc.subject.keywordPlus | overall survival | - |
dc.subject.keywordPlus | pneumonia | - |
dc.subject.keywordPlus | progression free survival | - |
dc.subject.keywordPlus | retrospective study | - |
dc.subject.keywordPlus | survival rate | - |
dc.subject.keywordAuthor | Autologous transplantation | - |
dc.subject.keywordAuthor | Diffuse large B-cell lymphoma | - |
dc.subject.keywordAuthor | Hematopoietic stem cell transplantation | - |
dc.subject.keywordAuthor | Rituximab | - |
dc.subject.keywordAuthor | Survival analysis | - |
dc.identifier.url | https://synapse.koreamed.org/articles/1092131 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.